doi: 10.1016/j.bone.2014.07.030 18 DriessenJHvan OnzenoortHAStarup-LindeJHenryRNeefCvan den BerghJet al
To determine whether this was true, researchers pooled data from observational studies and clinical trials that included type 2 diabetes patients taking a GLP-1RA.On average, 66.7% of patients taking GLP-1RAs also took a long-acting insulin (mean dose, 0.42 +- 0.32 units/kg/d)
The most important factor is adherencechoosing a time that fits naturally into daily routines maximises treatment compliance and therapeutic benefit
Many patients starting semaglutide (Ozempic, Wegovy, Rybelsus) wonder whether their daily coffee habit is compatible with treatment
For many patients, these injectables deliver the most consistent, clinically proven reductions in body weight
What is the difference between tirzepatide glycine B12 and tirzepatide B12 only